Me-too diabetes drugs look good enough for Lilly

June 26, 2013
Back to TopCommentsE-mailPrintBookmark and Share

Who says the age of me-too drugs is over?

Eli Lilly and Co. is more than 15 years late to the game in the world of diabetes drugs. And it isn’t bringing much that doctors and patients haven’t already seen.

Still, with diabetes getting out of control across the globe, it looks like Lilly has arrived in time to make a few billion a year.

The Indianapolis-based drugmaker was the global pioneer in diabetes medicines when it introduced the first animal-based insulin in 1923 and the first biotech insulin in 1982.

But as I have described before, Lilly missed the boat in the late 1990s and early 2000s on non-insulin medicines for Type 2 diabetics—particularly oral medications that don’t require injections, something patients desperately try to avoid.

Lilly’s sales of diabetes medicines have been growing only about half as fast as its competitors ever since.

But Lilly appears to be staging a comeback. It rolled out a raft of data about its diabetes drugs this past weekend. The numbers look good.

Problem is, they don’t look any better than drugs that are already on the market. Lilly’s experimental drug dulaglutide will compete with Novo Nordisk A/S’ Victoza and Bristol-Myers Squibb Co.’s Bydureon. Lilly’s empagliflozin will compete with Johnson & Johnson’s Invokana, which recently won approval from U.S. regulators.

“There does not appear to be much clinical differentiation in terms of efficacy and side effects,” wrote Morgan Stanley David Risinger, in a June 24 note to investors. Marc Goodman, a pharmaceutical analyst at UBS, said the same.

Still, Lilly will likely find customers, for a couple of reasons. First, dulaglutide is a once-weekly medicine, compared with Victoza’s daily dose. Results of a head-to-head trial of the two drugs are due early next year.

Also, the new drugs will allow Lilly to offer a whole range of medicines to diabetics, not just its insulins. And that portfolio approach will help it pick up sales, since patients and doctors often like to stick with one manufacturer throughout the course of their disease.

“In our view, Lilly will benefit from having a broader portfolio of diabetes drugs that covers the entire treatment paradigm,” Risinger wrote.

By 2020, Lilly could pull in roughly $1 billion each from dulaglutide, empagliflozin and a new long-acting insulin, according to Risinger. He gives the drugs 85 percent or 90 percent chances of being approved.

Other analysts have roughly similar estimates.

Extra sales of $3 billion a year are just what the doctors at Lilly ordered. That’s because the company is in the process of losing nearly $10 billion in annual sales because of patent expirations between 2010 and 2014 on four of its blockbuster drugs.

Of course, $3 billion does not equal $10 billion. So Wall Street analysts want to see something else, such as Lilly’s experimental cancer drug ramucirumab. Lilly is trying to differentiate that drug from Avastin, which has become a $3-billion-a-year powerhouse as a treatment against numerous kinds of cancer.

Some are optimistic, but as I wrote earlier this month, recent failures made others jittery.

“With the upcoming expirations of Cymbalta and Evista, we are less than optimistic on Lilly’s late stage pipeline being able to account for the sales cliff post-2014,” Goodman wrote to investors on June 25.

But Lilly has shown a remarkable ability to wring sales out of me-too drugs. Consider its current best-seller Cymbalta. When approved in 2004, it was the umpteenth antidepressant on the market. Yet the drug has actually accelerated its sales late in its life, rising from $3 billion in 2009 to $5 billion last year.

The Lilly brass are banking more than a little that they can keep it up for a few more years until, they hope, their pipeline produces a game-changer.

What do you all think? Can me-too drugs be enough to help Lilly muddle through its challenges that lie ahead?

  • Facts vs PR
    Data released this week by EvaluatePharma shows that in 2012, Lilly's sales of biotech products (of which insulin is part) ranked 9th in the world at $5.3 billion. This was well below the leader, Roche, with $26.7 billion. Can Lilly explain how it fell so far behind in a market that it created? If one listens to Lilly's corporate pronouncements over the last 15 years, they are replete with glorification of what was in effect under-performance. Lilly still has one of the most respected R&D organization in the industry. But the fact that so many talented people have not really brought much to the market since 2004 raises disturbing questions about the company's failure to harness its creative assets. Unless this situation is addressed head-on, and radical changes are made, there is every reason to fear that Lilly's disastrous biotech performance will repeat itself -- and will be labeled a great achievement. The company clearly faces a leadership issue that the board must address. Worldwide Prescription Drug Sales from Biotechnology in 2012: 1. Roche $26.7 bn 2. Amgen: $15.5 3. Sanofi: $13.4 4. Novo: $12.6 5. Pfizer: $10.3 6. Abbvie: $10.1 7. J&J: $8.1 8: Merck: 7.4 9. Lilly: 5.3 10. GSK: 4.8
  • prof of curmudgeony
    The problem with science, medicine and the stock market is that accurately predicting the future is impossible. We keep trying because it is fun. Lilly has strong management, good science and is investing heavily in taking chances. They are the historic leader in diabetes and it makes sense to broaden that franchise. We can't know which drugs will be better for which patients until we get a lot of data. Anticipate surprises, but don't fear them. Fear causes disease.

Post a comment to this blog

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
  1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

  2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

  3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

  4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

  5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.